Heather Brechbuhl, PhD

Publications

• Brechbuhl HM, Han A, Paul KV, Nemkov T, Ramachandran S, Ward A, Jacobsen BM, Hansen K, Sartorius CA, D'Alessandro A, Kabos P. Metabolic Switch in Endocrine Resistant Estrogen Receptor Positive Breast Cancer. bioRxiv. 2024 Dec 29. PubMed PMID: 39763830
• Brechbuhl HM, Sartorius CA. Sticky Business: Progesterone Receptors Mediate Cancer Associated Fibroblast and Breast Cancer Cell Interaction. Endocrinology. 2024 Aug 27;165(10). PubMed PMID: 39212483
• Ward AV, Riley D, Cosper KE, Finlay-Schultz J, Brechbuhl HM, Libby AE, Hill KB, Varshney RR, Kabos P, Rudolph MC, Sartorius CA. Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cells. bioRxiv. 2024 Dec 19. PubMed PMID: 38895323
• Ellen E. Bamberg, Kiran Vinod-Paul, Amy L. Han, Kirk Hansen, Carol Sartorius, Peter Kabos, Heather M Brechbuhl. Fibroblast in the Obese Tumor Microenvironment Enhance Breast Cancer Progression. Poster Presentation by Ellen Bamberg at the 2022 Cancer Biology Training Program Retreat at YMCA Snow Mountain Ranch, CO. October 20, 2022
• Amy L. Han, Kiran Vinod-Paul, Satyanarayan Rao, Heather M. Brechbuhl, Carol A. Sartorius, Srinivas Ramachandran, Peter Kabos. Estradiol (E2) concentration shapes the chromatin binding landscape of the estrogen receptor. bioRxiv 2022.09.23.509212; dot: https://doi.org/10.1101/2022.09.23.509212
• Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2021 Dec 2. [Epub ahead of print] PubMed PMID: 34856027
• Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 Oct;59(10):1129-1139. PubMed PMID: 32822091
• Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020 Feb 27;5(4). PubMed PMID: 32045383
• Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 Jul 25;3(14). [Epub ahead of print] PubMed PMID: 30046001
• Brechbuhl HM, Barrett A, Kopin E, Gillen AE, Hagen J, Finlay-Shultz J, Sartorius CA, Hansen K, Kabos P. Proteomic Analysis of Extracellular Matrix Helps Define Drivers of Metastatic Progression. San Antonio Breast Cancer Symposium. December 2018.
• Gillen AE, Brechbuhl HM, Yamamoto TM, Kline E, Pillai MM, Hesselberth JR, Kabos P. Alternative Polyadenylation of PRELID1 Regulates Mitochondrial ROS Signaling and Cancer Outcomes. Mol Cancer Res. 2017 Dec;15(12):1741-1751. PubMed PMID: 28912168
• Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Cancer Res. 2017 Sep 15;77(18):4934-4946. PubMed PMID: 28729413
• Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2016 Oct 4. [Epub ahead of print] PubMed PMID: 27702820

Practice Locations

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Specialty Information

Specialties

• Medical Oncology